Initial phase II results of Arzerra in DLBCL released
Results have been announced from a phase II study of Arzerra (ofatumamab) in the treatment of diffuse large B-cell lymphoma (DLBCL). 81 patients were involved in the single-arm study, the majority of them heavily pre-treated by rituximab or a stem cell transplant.
The study's primary endpoint was overall response rate (ORR), which was observed to be just 11% after a median of 6,9 months. These kinds of results will make it difficult for the manufacturer to get it approved for DLBCL.
The FDA initially approved Arzerra (ofatumamab) in November 2009 under its accelerated approval process for relapsed or refractory chronic lymphocytic leukemia.
HEMATOLOGICAL CANCER TYPE(S)
Diffuse large B-cell lymphoma (DLBCL)
WHERE WAS THIS RESEARCH PUBLISHED?
The data has not yet been published.
Source
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
